Biofil Chemicals & Pharmaceuticals Ltd
Incorporated in 1993, Biofil Chemicals and Pharmaceuticals Ltd deals in Pharmaceuticals and Chemicals products.[1]
- Market Cap ₹ 47.8 Cr.
- Current Price ₹ 29.4
- High / Low ₹ 46.8 / 25.6
- Stock P/E 91.9
- Book Value ₹ 13.4
- Dividend Yield 0.00 %
- ROCE 2.97 %
- ROE -2.83 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -4.50% over past five years.
- Company has a low return on equity of 1.24% over last 3 years.
- Earnings include an other income of Rs.0.38 Cr.
- Company has high debtors of 355 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.86 | 13.17 | 13.45 | 12.36 | 23.13 | 29.69 | 35.75 | 22.38 | 30.04 | 40.04 | 33.40 | 28.40 | 22.45 | |
| Sales growth | -18.27% | +124.74% | +2.13% | -8.10% | +87.14% | +28.36% | +20.41% | -37.40% | +34.23% | +33.29% | -16.58% | -14.97% | -47.20% |
| 5.12 | 12.30 | 10.84 | 11.43 | 22.11 | 27.87 | 34.15 | 21.05 | 28.88 | 39.23 | 32.55 | 27.75 | 21.69 | |
| Operating Profit | 0.74 | 0.87 | 2.61 | 0.93 | 1.02 | 1.82 | 1.60 | 1.33 | 1.16 | 0.81 | 0.85 | 0.65 | 0.76 |
| OPM % | 12.63% | 6.61% | 19.41% | 7.52% | 4.41% | 6.13% | 4.48% | 5.94% | 3.86% | 2.02% | 2.54% | 2.29% | 3.39% |
| 0.46 | 0.53 | 0.14 | 0.10 | 0.10 | 0.17 | 0.80 | 0.15 | 0.10 | 0.49 | 0.31 | 3.08 | 0.38 | |
| Interest | 0.21 | 0.15 | 0.16 | 0.15 | 0.16 | 0.12 | 0.07 | 0.04 | 0.04 | 0.04 | 0.04 | 0.01 | 0.01 |
| Depreciation | 0.25 | 0.26 | 0.28 | 0.30 | 0.37 | 0.41 | 0.41 | 0.43 | 0.43 | 0.40 | 0.38 | 0.27 | 0.28 |
| Profit before tax | 0.74 | 0.99 | 2.31 | 0.58 | 0.59 | 1.46 | 1.92 | 1.01 | 0.79 | 0.86 | 0.74 | 3.45 | 0.85 |
| Tax % | 20.27% | 20.20% | 22.51% | 20.69% | 20.34% | 17.81% | 34.90% | 31.68% | 29.11% | 17.44% | 24.32% | 19.13% | |
| 0.59 | 0.78 | 1.79 | 0.47 | 0.48 | 1.21 | 1.24 | 0.70 | 0.56 | 0.71 | 0.56 | 2.79 | 0.52 | |
| EPS in Rs | 0.36 | 0.48 | 1.10 | 0.29 | 0.29 | 0.74 | 0.76 | 0.43 | 0.34 | 0.44 | 0.34 | 1.71 | 0.32 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | -5% |
| 3 Years: | -2% |
| TTM: | -47% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -82% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | -13% |
| 3 Years: | -16% |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 2% |
| 3 Years: | 1% |
| Last Year: | -3% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 |
| Reserves | -7.86 | -5.37 | -3.58 | -3.11 | -2.62 | -1.39 | -0.14 | 0.56 | 1.03 | 1.93 | 2.51 | 5.29 | 5.51 |
| 2.98 | 1.37 | 1.43 | 1.56 | 1.64 | 1.19 | 0.43 | 0.46 | 0.52 | 0.44 | 0.47 | 3.02 | 2.17 | |
| 2.36 | 11.87 | 7.72 | 9.44 | 8.93 | 26.30 | 16.68 | 1.44 | 13.58 | 28.44 | 31.70 | 18.26 | 29.37 | |
| Total Liabilities | 13.75 | 24.14 | 21.84 | 24.16 | 24.22 | 42.37 | 33.24 | 18.73 | 31.40 | 47.08 | 50.95 | 42.84 | 53.32 |
| 9.06 | 8.98 | 9.16 | 9.25 | 10.29 | 10.09 | 9.78 | 9.42 | 9.00 | 8.62 | 8.34 | 6.94 | 6.89 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 4.69 | 15.16 | 12.68 | 14.91 | 13.93 | 32.28 | 23.46 | 9.31 | 22.40 | 38.46 | 42.61 | 35.90 | 46.43 | |
| Total Assets | 13.75 | 24.14 | 21.84 | 24.16 | 24.22 | 42.37 | 33.24 | 18.73 | 31.40 | 47.08 | 50.95 | 42.84 | 53.32 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.01 | 0.14 | 0.71 | 0.46 | 1.26 | 0.89 | 1.11 | -0.22 | -0.11 | 2.39 | -1.92 | -0.60 | |
| -0.17 | -0.19 | -0.48 | -0.38 | -1.41 | -0.21 | -0.10 | -0.07 | -0.01 | -0.02 | -0.10 | 1.14 | |
| 0.11 | 0.10 | -0.11 | -0.02 | -0.08 | -0.57 | -0.83 | -0.01 | 0.02 | -0.12 | 0.00 | 2.54 | |
| Net Cash Flow | -0.05 | 0.05 | 0.13 | 0.06 | -0.24 | 0.12 | 0.18 | -0.30 | -0.11 | 2.25 | -2.03 | 3.07 |
| Free Cash Flow | -0.16 | -0.05 | 0.23 | 0.08 | -0.15 | 0.68 | 1.01 | -0.29 | -0.12 | 2.37 | -2.02 | 0.54 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 19% | 33% | 35% | 103% | 134% | 63% | 112% | 8% | 10% | 314% | -205% | 9% |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 227.35 | 387.45 | 311.00 | 383.31 | 189.84 | 365.25 | 175.81 | 116.94 | 249.08 | 301.10 | 418.77 | 354.59 |
| Inventory Days | 15.99 | 3.46 | 7.29 | 38.11 | 21.73 | 24.37 | 48.85 | 24.20 | 16.11 | 24.81 | 39.52 | 56.24 |
| Days Payable | 198.49 | 400.98 | 304.52 | 341.46 | 156.66 | 373.80 | 178.39 | 11.25 | 168.39 | 268.08 | 366.66 | 239.87 |
| Cash Conversion Cycle | 44.85 | -10.07 | 13.76 | 79.95 | 54.90 | 15.82 | 46.27 | 129.88 | 96.80 | 57.83 | 91.63 | 170.96 |
| Working Capital Days | -47.96 | 48.50 | 87.65 | 104.83 | 50.81 | 55.69 | 64.12 | 125.25 | 104.25 | 69.37 | 114.09 | 152.17 |
| ROCE % | 8.59% | 9.64% | 18.72% | 5.06% | 5.00% | 10.08% | 12.20% | 6.20% | 4.73% | 4.94% | 4.12% | 2.97% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Chemicals Segment Revenue INR Lakhs |
|
||||||||||
| Permanent Employees count |
|||||||||||
| Pharma Segment Revenue INR Lakhs |
|||||||||||
| Vacant Land at Pithampur sq meters |
|||||||||||
| Related Party Purchases from Cyano Pharma (CPPL) INR Lakhs |
|||||||||||
| Related Party Sales to Cyano Pharma (CPPL) INR Lakhs |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Submission of publication of Un-audited financial results in the Newspaper pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015.
-
To Review, Consider And Approve The Standalone Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2026 Along With Limited Review Report.
- Board approved Q2 FY26 results; manufacturing facility upgradation expected in 3-6 months.
-
Board Meeting Outcome for Board Meeting Outcome To Review, Consider And Approve The Standalone Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2026 Along With Limited Review Report
- Q2 FY27 results: PAT Rs 11.53 lakh, board approved on 14 Nov 2026; facility upgradation in 3-6 months.
-
Board Meeting Intimation for For Consideration And Approval Of Unaudited Financial Results Of The Company For The Quarter And Half Year Ended On 30Th
September, 2026 Along With Limited Review Report Thereon.
- Board to meet on 14 Nov 2026 to approve Q2/H1 FY27 unaudited results; trading window remains closed.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Certificate under Regulation 74(5) of the SEBI (Depository and Participants) Regulations, 2018 for the quarter ended 30th September, 2026
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1]
BCPL is engaged in diverse pharmaceutical activities including manufacture and trading
of various pharmaceutical and chemical products. It also deals in providing job work facility in respect of manufacturing of pharmaceuticals drug. The company runs its business via 2 units viz. Pharmaceutical Division & Chemicals Division.